Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AbobotulinumtoxinA with guided self-rehabilitation for adult spastic hemiparesis
2016-001989-29Phase 3Completed
- Sponsor
- Ipsen
- Start
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in spastic hemiparesis, sponsored by Ipsen. Primary endpoint: Primary efficacy endpoint. Started Aug 2016; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
spastic hemiparesis
Beyond the preview
Go deeper on 2016-001989-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001989-29.